enVVeno Medical Narrows Q2 Loss 46%, Extends Cash Runway to Q3 2027 as Pivotal Trial Nears
NVNO sits 23% above its 52-week low of $8.67 on light trading volume (0.2× avg).
Summary
enVVeno Medical reported a 46% narrower Q2 net loss of $3.6 million and extended its cash runway to Q3 2027, while confirming the pivotal trial for its enVVe venous valve will begin later this year.
Key Events · Earnings and Guidance · NVNO
-
Q2 Loss Narrows 46%
Net loss fell to $3.6 million from $6.7 million a year ago, driven by lower R&D and SG&A expenses as the VenoValve study winds down.
-
Cash Runway Extended to Q3 2027
Cash and investments totaled $21.5 million at June 30, 2026. Management expects the burn rate to rise to $4–5 million per quarter in H2 2026 but still sees funding into Q3 2027.
-
Pivotal Trial to Start H2 2026
FDA IDE approval was received in April 2026. The first 10-patient stage of the TAVVE study is expected to commence in the second half of 2026, with 30-day safety data submitted to the FDA.
-
Minimal ATM Dilution in Q2
Only 17,000 shares were issued under the at-the-market program during the quarter, raising net proceeds of $0.1 million.
Analysis · NVNO · Industrial Applications And Services
enVVeno Medical cut its quarterly net loss nearly in half to $3.6 million while holding $21.5 million in cash and investments — enough to fund operations into the third quarter of 2027. The company also confirmed FDA approval of its IDE for the enVVe venous valve pivotal study, with the first 10-patient stage expected to begin in the second half of 2026. The improved burn rate and extended runway reduce near-term dilution risk, but the company still needs to raise additional capital before commercialization.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVNO was trading at $10.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $8.67 to $184.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.